ERX-315 SUBMITTED FOR HREC APPROVAL

Dallas, TX – May 14th, 2024 - Etira is pleased to announce the submission of the regulatorydocuments for approval of administration of its breakthrough oncology drug ERX-315 to theHuman Research Ethics Committee (HREC) in Australia.…

ERX-208 potency in Ovarian Cancer

San Diego, CA. April 10, 2024: Etira founder Dr Ratna Vadlamudi’s laboratory presents comprehensive data on the activity of ERX-208 in ovarian cancer. ERX-208 is active against all four molecular subtypes of ovarian cancer and its activity…

Targeting LIPA in ovarian cancer

Dallas, TX. January 24, 2024: We are pleased to present a manuscript in Cancers from the laboratory of Etira founder Dr. Ratna Vadlamudi. The data presented show that ERX-41 targets LIPA in ovarian cancer and is effective against all 4 subtypes…

ERX-315 introduced at SABCS 2023

San Antonio, TX. December 7, 2023: Etira is pleased to present the data with its lead compound ERX-315 that cause catastrophic levels of ER stress, resulting in breast cancer cell death, and that can successfully function against multiple forms…

Independent validation of LIPA as a molecular target in TNBC

Dallas, TX. October 2, 2023: Etira is pleased to note the independent validation of LIPA as a molecular target in TNBC in a preprint in biorxiv from Dr. Esser’s group in Dusseldorf, Germany. The authors conclude that LIPA-activity is a novel…

One year later, highest almetric score for any paper published in Nature Cancer!

 Dallas, Texas. June 1, 2023:   One year after its online publication, we are pleased to note that our manuscript titled “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid…

Positive preclinical data presented at AACR 2023

 Dallas, Texas. April 18, 2023: Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The data, presented…

Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award

Dallas, Texas. April 17, 2023:We are excited to congratulate one of our founders, Dr. Ratna Vadlamudi, Professor and Vice Chair for Research, Division of Reproductive Research, Department of Obstetrics & Gynecology, Long School of…

Preclinical data on TNBC presented at SABCS 2022

Dallas, Texas. December 9, 2022: Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast Cancer Symposium (SABCS). The SABCS is one of the world's…

Etira founder Dr. Jung-Mo Ahn highlighted in local press

Dallas, Texas. October 31, 2022. We are pleased to share two news articles from Dallas that describe how our brilliant chemist and founder, Dr. Jung-Mo Ahn discovered ERX-41. In his words, Dr. Ahn describes the discovery of ERX-41 as “It’s…